Blue Cohosh, A Potential Teratogen, Needs Additional Study - FDA Scientist
This article was originally published in The Tan Sheet
Executive Summary
The dietary supplement blue cohosh is a potential teratogen that requires additional research, FDA Center for Food Safety & Applied Nutrition researcher Joseph Betz, PhD, told the National Institute of Environmental Health Sciences meeting on medicinal herbs in Raleigh, N.C. Sept. 23-24.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning